Attend the FierceBiotech Executive Breakfast at BIO 2019
Join us on June 5th for our panel discussion on real-world evidence. Reserve your seat today.
The deal will give Merck control of an experimental oral HIF-2α inhibitor that may challenge Keytruda for the metastatic renal cell carcinoma market.
Biotech-CRO hybrid Evotec is continuing its buying and collaborating strategy with its acquisition of U.S. biologics company Just Biotherapeutics.
Mount Sinai researchers showed that in male mouse models of heart attack, Cdx2 placental cells regenerated damaged tissue.
The Medicines Company announced long-term data for inclisiran, showing that the drug lowered “bad” LDL cholesterol by more than 50%.
Computing-enabled R&D shop Schrödinger will use its $110 million haul to advance its nascent pipeline of wholly owned drugs.
The pipeline of drugs and vaccines aimed at diseases prevalent in low- and middle-income countries has more than doubled since 2014.
British biotech is often a disregarded backwater in life sciences, but today a host of good news has shone the spotlight back onto its potential.
AbbVie became yet another biopharma learning that aggressive brain cancer glioblastoma is one of the toughest cancers out there.
Yale researchers discovered that AstraZeneca’s anti-VEGF cancer drug cediranib may boost the effectiveness of PARP inhibitors.
With the Shire deal done, Takeda is looking to lighten the load a little from its central R&D base. To that end, it has launched a new biotech, Phathom.
